Macquarie Group
VRDN icon

Macquarie Group’s Viridian Therapeutics VRDN Stock Holding History

Macquarie Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-154,739
Closed -$3.34M – 1489
2025
Q3 		$3.34M Sell
154,739
-2,428
-2% -$43.8K ﹤0.01% 1032
2025
Q2 		$2.2M Sell
157,167
-3,781
-2% -$51.3K ﹤0.01% 1194
2025
Q1 		$2.17M Buy
160,948
+18,555
+13% +$316K ﹤0.01% 1193
2024
Q4 		$2.73M Sell
142,393
-1,002
-0.7% -$21.8K ﹤0.01% 1096
2024
Q3 		$3.26M Buy
143,395
+114,025
+388% +$1.86M ﹤0.01% 1082
2024
Q2 		$382K Buy
+29,370
New +$407K ﹤0.01% 1497
2018
Q2 		– Sell
-287
Closed -$30K – 2282
2018
Q1 		$30K Buy
+287
New +$31.2K ﹤0.01% 2044

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Macquarie Group's VRDN Position: Q4 2025 in Review

Macquarie Group sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 154,739 shares — an estimated $3.34M sold.

Macquarie Group first reported a position in VRDN in Q1 2018 and held it in 7 quarters. The position peaked at $3.34M in Q3 2025. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Macquarie Group reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 154,739 Viridian Therapeutics shares in Q4 2025, an estimated $3.34M.
  • Macquarie Group first reported a position in Viridian Therapeutics in Q1 2018 and held it in 7 quarters.
  • Macquarie Group's Viridian Therapeutics position peaked at $3.34M in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.